Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis?

被引:20
作者
Barcena, R [1 ]
Oton, E
Moreno, MA
Fortún, J
Garcia-Gonzalez, M
Moreno, A
de Vicente, E
机构
[1] Hosp Ramon y Cajal, Serv Hepatogastroenterol, E-28034 Madrid, Spain
[2] Hosp Ramon y Cajal, Internal Med Serv, E-28034 Madrid, Spain
[3] Hosp Ramon y Cajal, Infect Dis Serv, E-28034 Madrid, Spain
[4] Hosp Ramon y Cajal, Gen Surg Serv, E-28034 Madrid, Spain
关键词
Infection; liver failure; liver transplantation; toxicity;
D O I
10.1111/j.1600-6143.2005.01065.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Antituberculous treatment is a well-known cause of fulminant hepatic failure (FHF). This could lead to liver transplantation as the only possible treatment, which on the other hand could be contraindicated due to active tuberculosis. The risk of aggressive dissemination of the disease after transplantation is not clearly determined by the current second-line antituberculous therapies. We report a case of vertebral tuberculosis treated with rifampin, isoniazid and pyrazinamide. He developed an FHF that was treated with urgent liver transplantation. Despite the immunosuppression, the disease was well controlled with ciprofloxacin, ethambutol and streptomycin and the patient is in good health 23 months after transplantation. In conclusion, active extrapulmonary tuberculosis should perhaps be considered for liver transplantation when FHF develops due to anti-tuberculous drugs.
引用
收藏
页码:2796 / 2798
页数:3
相关论文
共 13 条
[1]
Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain [J].
Aguado, JM ;
Herrero, JA ;
Gavalda, J ;
TorreCisneros, J ;
Blanes, M ;
Rufi, G ;
Moreno, A ;
Gurgui, M ;
Hayek, M ;
Lumbreras, C ;
Morales, JM ;
Pahissa, A ;
Margerit, C ;
Prada, JL ;
Kindelan, JM ;
Ros, F ;
Pallardo, LM ;
Carratala, J ;
Gudiol, F ;
Gonzalez, J ;
Vilardell, J ;
Guirado, L ;
Rabella, N .
TRANSPLANTATION, 1997, 63 (09) :1278-1286
[2]
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[3]
RISK-FACTORS FOR ISONIAZID (INH)-INDUCED LIVER DYSFUNCTION [J].
DICKINSON, DS ;
BAILEY, WC ;
HIRSCHOWITZ, BI ;
SOONG, SJ ;
EIDUS, L ;
HODGKIN, MM .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1981, 3 (03) :271-279
[4]
TREATMENT OF HEPATIC-FAILURE SECONDARY TO ISONIAZID HEPATITIS WITH LIVER-TRANSPLANTATION [J].
FARRELL, FJ ;
KEEFFE, EB ;
MAN, KM ;
IMPERIAL, JC ;
ESQUIVEL, CO .
DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (10) :2255-2259
[5]
ISONIAZID-ASSOCIATED HEPATITIS - REPORT OF AN OUTBREAK [J].
GARIBALDI, RA ;
FEREBEE, SH ;
GREGG, MB ;
DRUSIN, RE .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1972, 106 (03) :357-+
[6]
Cytochrome p450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis [J].
Huang, YS ;
Chern, HD ;
Su, WJ ;
Wu, JC ;
Chang, SC ;
Chiang, CH ;
Chang, FY ;
Lee, SD .
HEPATOLOGY, 2003, 37 (04) :924-930
[7]
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis [J].
Huang, YS ;
Chern, HD ;
Su, WJ ;
Wu, JC ;
Lai, SL ;
Yang, SY ;
Chang, FY ;
Lee, SD .
HEPATOLOGY, 2002, 35 (04) :883-889
[8]
MEYERS BR, 1994, TRANSPLANTATION, V58, P372
[9]
Tuberculosis in orthotopic liver transplant patients: Increased toxicity of recommended agents; Cure of disseminated infection with nonconventional regimens [J].
Meyers, BR ;
Papanicolaou, GA ;
Sheiner, P ;
Emre, S ;
Miller, C .
TRANSPLANTATION, 2000, 69 (01) :64-69
[10]
ISONIAZID LIVER-INJURY - CLINICAL SPECTRUM, PATHOLOGY, AND PROBABLE PATHOGENESIS [J].
MITCHELL, JR ;
ZIMMERMAN, HJ ;
ISHAK, KG ;
THORGEIRSSON, UP ;
TIMBRELL, JA ;
SNODGRASS, WR ;
NELSON, SD .
ANNALS OF INTERNAL MEDICINE, 1976, 84 (02) :181-192